Ignite Creation Date:
2024-05-06 @ 6:53 PM
Last Modification Date:
2024-10-26 @ 2:56 PM
Study NCT ID:
NCT05812430
Status:
RECRUITING
Last Update Posted:
2023-09-13
First Post:
2023-03-13
Brief Title:
Anlotinib Plus TQB2450 Combined With Nab-paclitaxel and Cisplatin as First-line Treatment for Advanced Biliary Tract Cancer
Sponsor:
The First Affiliated Hospital of Zhengzhou University
Organization:
The First Affiliated Hospital of Zhengzhou University
Key Dates - Follows AllAPIJSON File Order
Start Date:
2023-04-10
Start Date Type:
ACTUAL
Primary Completion Date:
2023-10-10
Primary Completion Date Type:
ESTIMATED
Completion Date:
2024-10-10
Completion Date Type:
ESTIMATED
First Submit Date:
2023-03-13
First Submit QC Date:
April 2 2023
Study First Post Date:
2023-04-13
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-09-09
Last Update Post Date:
2023-09-13
Last Update Post Date Type:
ACTUAL